Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798346 | 0.92 | KMT2A (0.41) | TLR9GAASMN1; SMN2CA1CA2 | |
| SCHEMBL16055972 | 0.92 | UTS2R (0.43) | GAASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL6423000 | 0.92 | TP53 (0.43) | GAAALDH1A1MEN1KMT2A | |
| SCHEMBL4801050 | 0.92 | RAPGEF4 (0.40) | TLR9GAASMN1; SMN2CA1CA2 | |
| SCHEMBL989351 | 0.92 | NPY2R (0.44) | TLR9GAASMN1; SMN2CA1CA2 | |
| SCHEMBL22730498 | 0.89 | ALDH1A1 (0.43) | CA1CA2CA12CA9CA5A | |
| SCHEMBL16093818 | 0.89 | KMT2A (0.46) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL5741463 | 0.85 | KMT2A (0.40) | TLR9CA1CA2CA12CA9 | |
| SCHEMBL13073968 | 0.84 | CA12 (0.46) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL22858205 | 0.84 | PTGS2 (0.36) | TLR9GAASMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619204-B1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2022-12-01 | — | — | US | disclosed |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | TLR9 2419/4885GAA 1769/4885SMN1; SMN2 2531/4885 |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | TLR9 518/4885GAA 380/4885SMN1; SMN2 3328/4885 |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | TLR9 518/4885GAA 380/4885SMN1; SMN2 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.